Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Non-invasive Brain Stimulation System Market size was over USD 701.4 million in 2024 and is estimated to reach USD 1.5 billion by the end of 2037, expanding at a CAGR of 7.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of non-invasive brain stimulation system is evaluated at USD 751.2 million.
Disrupted quality of life due to the impact of cognitive and chronic neurological disorders are igniting demand in the non-invasive brain stimulation system market. As the population of habitats with depression, epilepsy, Parkinson’s, and Alzheimer disease grows, the need for more effective and accessible solutions rises. According to the March 2024 Lancet Neurology article, the number of neurologically-impaired individuals across the world reached 3.4 billion in 2021. The report further stated that the disability-adjusted-life-years (DALYs) were counted to be 443.0 million, with an 18.0% increment from 1990 to 2021. These figures testify these conditions to be the leading cause of fatalities every year, dragging the focus of worldwide health organizations to invest in this sector.
The enlarging burden of treatment cost is creating a new trend of establishing standardized pricing for the non-invasive brain stimulation system market. The efforts from various authorized institutions and R&D teams are helping companies bring more affordable and accessible solutions through their revolutionary findings. They are meticulously trying to obtain generic forms of advanced devices that can serve remotely, eliminating the need for specialized inhibition and cost of hospitalization. However, the current payers’ pricing of these tools may vary as per the region and disease type. It was showcased by a systematic review, published in an NLM journal, in March 2024, revealing the inflation- and currency-adjusted mean cost of the deep brain stimulation (DBS) device to be USD 21,496.07 ± USD 8,944.16 in 2022.
Country-wise mean cost of DBS treatment and surgery (2022)
|
Country |
Surgery (USD) |
Treatment (USD) |
|
The U.S. |
53,266,2000.0 |
62,457,8000.0 |
|
The UK |
48,941,6667.0 |
53,711,5000.0 |
|
Spain |
43,760,0000.0 |
50,586,3333.0 |
|
Korea |
33,309,0000.0 |
39,147,0000.0 |
|
Japan |
16,487,0000.0 |
18,829,0000.0 |
|
Germany |
36,436,6667.0 |
50,365,3333.0 |
|
China |
47,294,5000.0 |
50.853,0000.0 |
|
Canada |
31,515,0000.0 |
32,739,0000.0 |
Source: The U.S. Bureau of Labor Statistics Inflation Calculator
Non-invasive Brain Stimulation System Market: Growth Drivers and Challenges
Growth Drivers
- Increased research and clinical applications: As exploration progresses in the non-invasive brain stimulation system market, more therapeutic potential of these products is being introduced. For instance, in February 2024, Samphire Neuroscience launched a drug-free painkiller, Nettle, for women, undergoing menstrual cycle. The headband is specifically designed to offer relief from pre-menstrual symptoms (PMS) by stimulating the dorsolateral prefrontal cortex (DLPFC) in brain while eliminating the need for risky hormonal pills. Such pioneers of neurotechnology are fostering a strong foundation for this sector by broadening the range of consumer base and revolutionizing the conventional treatment approach.
- Growing demand for non-invasive treatments: One of the major drivers in the non-invasive brain stimulation system market is the lower surgical incisions and reduced hospital stays. Particularly, the rising popularity of precision neurology is empowering this concept with international collaborations between psychiatry and electrical engineering expertise and funding. For instance, in January 2025, the Advanced Research and Invention Agency (ARIA) invested USD 4.1 million to bring breakthroughs in minimally invasive deep brain stimulation technologies. This grant was a crucial part of accelerating its Precision Neurotechnologies programme for Parkinson’s disease. These initiatives are propelling this sector by introducing new faster and long-acting features.
Challenges
- The economic disparity and volatility: The variability in pricing of the products from the non-invasive brain stimulation system market is a major difficulty for wide adoption. High expenses of these devices and implantation processes becomes a hurdle in expanding the reach of this sector, specially in budget-constrained regions. On the other hand, the development and production cost make it hard for manufacturers to maintain suitable pricing. In addition, lack of adequate healthcare infrastructure in these areas shrinks the distribution channels, limiting market exposure.
- Lack of awareness about advanced modules: Rise in revenue figures in the non-invasive brain stimulation system market highly depends on the widespread awareness. Thus, the absence of proper educational campaigns and promotional activities in rural areas may become a hurdle in fostering consumer trust and adoption. Moreover, the shortage of skilled operators and surgeons, who are trained to utilize such clinical upgradations, may reduce the scope of showcasing its effectiveness. These combined factors are the primary hurdles in this sector’s expansion.
Non-invasive Brain Stimulation System Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.1% |
|
Base Year Market Size (2024) |
USD 701.4 million |
|
Forecast Year Market Size (2037) |
USD 1.5 billion |
|
Regional Scope |
|
Non-Invasive Brain Stimulation System Segmentation
Product (Transcranial Magnetic Stimulation (TMS) System, Transcranial Current Stimulation (TCS) System)
Based on product, the transcranial current stimulation (TCS) system segment is poised to hold non-invasive brain stimulation system market share of over 56.4% by the end of 2037. This technology is enriched with user-friendly operations and wide therapeutic application. Many clinical studies proved the efficacy of TCS in treating a wide spectrum of cognitive disorders including schizophrenia, OCD, depression, and others. The presence of sufficient clinical evidence around the efficacy and safety of this type of device is gaining faith from both consumers and healthcare professionals, making it more preferable over other options. In addition, its extensive use in clinical researches and patient monitoring is also a significant driver in this segment.
End user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics)
In terms of end user, the hospitals segment is anticipated to dominate the non-invasive brain stimulation system market throughout the assessed period. The presence and improvement of outpatient services in hospitals are also a factor of progress in this sector due to their economic contribution. For instance, the hospital section in India accounted for an 80.0% share of the total healthcare industry in 2021, which was estimated to value at USD 132.0 billion by 2023, as per NITI Aayog. In addition, the wide availability of all types of neurological assets including specialized surgeons, equipped operating rooms, and in-house pharmacological supply is a major reason behind patients opting for these facilities for treatment.
Our in-depth analysis of the global non-invasive brain stimulation system market includes the following segments:
|
Product |
|
|
End user |
|
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportNon-Invasive Brain Stimulation System Industry - Regional Synopsis
APAC Market Statistics
Asia Pacific non-invasive brain stimulation system market is set to hold revenue share of over 31% by the end of 2037. The broad network of consumers and increased investment in healthcare infrastructure is contributing to this region’s growth. For instance, in June 2023, the Department of Health and Aged Care in Australia allocated USD 73.0 million grant for 19 domestic projects. A notable part of the investment, USD 2.9 million, was directed to support R&Ds, which were involved with bringing technological innovations and alternatives for drug-free depression curative. Additionally, the government-issued promotional activities and accelerated regulatory approvals are opening new opportunities for both local and global leaders.
The rapid widespread of digitalization in India is garnering a pre-settled business environment for the non-invasive brain stimulation system market. On the other hand, the influence of governing bodies in encouraging domestic production of medical devices are fostering lucrative breaks for local companies. With these financial and regulatory support, the country is becoming a hub of cutting-edge medical technologies. For instance, the October 2021 IBEF report stated that the MedTech industry in India was counted to be USD 10.3 billion in 2020. The report further projected this to achieve USD 50.0 billion by 2025, exhibiting a CAGR of 37.0%. This indicates the progressive atmosphere of this landscape, backed by its excellence in 3D printing, artificial intelligence, smart sensors, and others.
China is feeding inflation in the non-invasive brain stimulation system market with efficiency in both demand and supply. The country’s strong emphasis in manufacturing medical devices and other instruments is evidence of its proprietorship in the international scenario. As per OEC, China ranked 3rd among the global exporters of medical instruments in 2023, securing an industry value of USD 12.3 billion. Another report from the International Trade Administration predicted China to follow a CAGR of 8.3% in the medical device industry till 2026, generating a value of USD 48.8 billion. These clarifies signifies the country’s efforts to accumulate better healthcare infrastructure with adequate facilities and services to improve accessibility and availability in this category.
North America Market Analysis
North America is predicted to register the fastest growth in the global non-invasive brain stimulation system market during the assessed timeframe. The region is pledged with the strong presence of neurotech leaders, who have secured an international recognition in delivering enhanced patient outcomes. The heightened popularity of wearables and upgraded neuro imaging facilities across established economies such as the U.S. and Canada is propelling advances in this field. In this regard, Research Nester projected that North America brain monitoring industry is estimated to hold the largest share of 40.0% by 2037. This privileged marketplace is cultivated to serve the emphasizing neurologically-impaired patient pool.
The spurred urge in the U.S. non-invasive brain stimulation system market is resulted by the current trend of penetrating advanced technologies into the mainstream healthcare. The improved outcomes and sufficient academic discoveries have raised the popularity of these advanced tools by presenting a suitable alternative to the traditional long-term methods. For instance, in February 2024, a team of scientists at Keck School of Medicine of USC unveiled the potential of AI in identifying the community of eligible residents with treatment resistant depression. The ENGIMA consortium presented a breakthrough in enhancing predictability in response rate of patients while applying repetitive transcranial magnetic stimulation (rTMS). Such clinical findings are creating new possibilities for this sector.
Canada is also following the way of rigorous R&D in becoming a global pioneer in the non-invasive brain stimulation system market. For instance, in 2024, the Canada Brain Research Fund allocated a grant of USD 80.0 million over four years for Brain Canada to empower its USD 160.0 million worth brain research initiative. With the stable capital influx from the federal government and favorable regulatory framework are accumulatively fostering a prosperous trading atmosphere for both local and foreign developers. The country is supporting the integration of technological discoveries to serve the geriatric habitats with better medical commodities. This is inspiring commercial stakeholders to engage their resources into the cohort.
Companies Dominating the Non-Invasive Brain Stimulation System Landscape
- Brainbox Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BrainsWay
- eNeura Inc.
- Flow Neuroscience
- Magnus Medical, Inc.
- Magstim
- MagVenture
- NeoSync, Inc. (Wave Neuroscience, Inc.)
- NeuraLace
- Neurocare Group AG
- NeuroMetrix
- Neuronetics
- Soterix Medical, Inc.
- Sinaptica Therapeutics, Inc.
- Medtronic plc
The collaborative and progressive nature of global leaders is a powerhouse of the non-invasive brain stimulation system market. Their intentions to improve product’s effectiveness and patient outcomes with continuous R&D activities are expanding the portfolio of this field. For instance, in January 2024, Magstim attained FDA approval for its revolutionary TMS system, Horizon 3.0 with StimGuide Pro to assist healthcare professionals in treating patients with depression and OCD. Similarly, in April of the same year, Soterix Medical announced the commercial launch of a combined high-definition transcranial electrical stimulation (HD-tES) and EEG system, MxN-GO EEG to elevate the operations for researchers by tracking real-time brain activities. This indicates to a well-diverse marketplace for MedTech pioneers. Such key players are:
In the News
- In February 2025, Sinaptica Therapeutics announced the initiation of a newly launched phase II study on its patent-pending, second-generation dual stimulation technology, SinaptiStim System. This tailored neuromodulation tool has already showed in retrieving memory among Alzheimer’s patients.
- In January 2025, MagVenture attained FDA clearance for marketing its TMS Atlas Neuro Navigation System in the U.S. market. The company aimed at establishing its strong presence in this category by delivering streamlined workflow for TMS treatment with precise and personalized coil positioning abilities.
- In January 2025, Medtronic plc gained CE (Conformité Européenne) Mark approval for its BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) from the European Union and the UK. This approval allowed the company to widen the reach of its pipeline for Parkinson's disease.
Author Credits: Radhika Pawar
- Report ID: 7229
- Published Date: Feb 27, 2025
- Report Format: PDF, PPT
